Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Brexucabtagene autoleucel
Trade Name Tecartus
Synonyms KTE-X19|KTEX19|KTE X19
Drug Descriptions

Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti-CD-19 chimeric antigen receptor (CAR), which may potentially target CD-19-expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory mantle cell lymphoma and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov).

CAS Registry Number NA
NCIT ID C170439


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Brexucabtagene autoleucel Brexucabtagene autoleucel 0 1
Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Brexucabtagene autoleucel Cyclophosphamide Fludarabine 0 3

Additional content available in CKB BOOST